Navigation Links
NTI in Biological Technology

Medical Simulation Corporation to Introduce Central Line Management Program at the National Teaching Institute and Critical Care Exposition

...l be presented at the MSC Booth (#1951) during the nti Critical Care Exposition, May 19-21, with opportunities for all nti attendees to participate in both types of simulati..., including training options, will be available at nti and can also be found online at www.medsimulatio...

Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company

...result in a transaction that meets our objectives, nti will act expeditiously to return as much cash as p...potential new drug to treat acute ischemic stroke. nti has recently chosen not to extend its early-stage ...a collaborative agreement with the Buck Institute. nti has rights to receive payments from an approved dr...

Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results

...ed product candidate, Viprinex(TM) (ancrod), which was studied in Phase 3 clinical trials for evaluation as a new drug to treat acute ischemic stroke. nti has an early-stage development program for Alzheimer's disease and rights to receive payments on an approved drug for Alzheimer's disease and an inves...

Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine

... treatment of Alzheimer's disease. Under an exclusive marketing agreement, nti currently receives quarterly royalty payments on certain sales of Memantine...inical trials for evaluation as a new drug to treat acute ischemic stroke. nti has an early-stage development program for Alzheimer's disease and rights t...

Neurobiological Technologies Announces Suspension of Viprinex Development

...mum necessary to carry out operations and complete contractual obligations. nti is terminating a majority of its employees this week, with additional emplo...linical trials for evaluation as a new drug to treat acute ischemic stroke. nti also has early-stage development programs for Alzheimer's and Huntington's ...

Neurobiological Technologies' Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009

...ic) has provided an update on XERECEPT(R). nti sold the worldwide rights and assets related to XERECEPT to Celtic in November 2005. nti is entitled to receive milestone payments upon the..., and if XERECEPT is approved for commercial sale, nti is also entitled to receive profit-sharing payment...

Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results

...trial, which we expect to complete by mid-2009." nti also announced that it has amended its stockholder...ed under the plan. Conference Call Information nti will webcast its quarterly financial results and h... which there are few acceptable treatment options. nti also has early-stage development programs for Alzh...

Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10

...nex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. nti also has early-stage development programs for Alzheimer's and Huntington's diseases, rights to receive payments on an approved drug for Alzheimer's di...

Neurobiological Technologies Sets Date for First Quarter Financial Results

...cute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. nti also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's...

Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine

...rate-to-severe Alzheimer's disease. Under an exclusive marketing agreement, nti currently receives quarterly royalty payments on certain sales of Memantine...diseases in the world for which there are few acceptable treatment options. nti also has early-stage development programs for Alzheimer's and Huntington's ...

Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008

...nex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. nti also has early-stage development programs for Alzheimer's and Huntington's diseases, rights to receive payments on an approved drug for Alzheimer's di...

Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program

...cute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. nti also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's...

Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit

...cute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. nti also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's...

Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine

...harmaceuticals GmbH (Merz) for sales of Memantine for the treatment of moderate-to-severe Alzheimer's disease. Under an exclusive marketing agreement, nti currently receives quarterly royalty payments on certain sales of Memantine by Merz and its marketing partners. About Neurobiological Technologies, ...

Neurobiological Technologies' CEO to Retire on December 31, 2008

...s sufficient time to thoughtfully identify my successor. I will direct our operations with vigor over the next six months and continue to be an active nti director beyond my retirement." A committee has been formed by the Board of Directors, headed by NTI director, William A. Fletcher, Chairman of Teva...

Neurobiological Technologies Reports Third Quarter Financial Results

...ion. During the three months ended March 31, 2008, nti wrote-down the value of its auction rate securitie...anial hemorrhage." Conference Call Information nti will webcast its quarterly financial results and h...tients can be treated after the onset of a stroke. nti also has the right to receive royalty payments fro...

Neurobiological Technologies Sets Date for Third Quarter Financial Results

...e the time period that patients can be treated after the onset of a stroke. nti also has the right to receive royalty payments from sales of Namenda(R) (me...inical development for swelling associated with brain tumors. Additionally, nti has rights to two compounds in early-stage development for Alzheimer's and ...

Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine

...antine for the treatment of moderate-to-severe Alzheimer's disease during the quarter ended December 31, 2007. Under an exclusive marketing agreement, nti currently receives quarterly royalty payments on certain sales of Memantine by Merz and its marketing partners. About Neurobiological Technologies, ...

Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens' Hospital

...30, 2008 of the royalties on sales of memantine in the third quarter of 2007 in the amount of $2,161,228. About Neurobiological Technologies, Inc. nti is a biopharmaceutical company focused on developing novel agents for central nervous system conditions. The Company's most advanced product candidate...

Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine

...emantine for the treatment of moderate-to-severe Alzheimer's disease for the quarter ended September 30, 2007. Under an exclusive marketing agreement, nti currently receives quarterly royalty payments on sales of Memantine by Merz and its marketing partners. Paul E. Freiman, President and CEO of Neurob...

Neurobiological Technologies Sets Date for Research and Development Day

...estions about the R&D Development Day can be directed to Walter Kass, NTI Investor Counsel, 212-300-4708. About Neurobiological Technologies, Inc. nti is a biopharmaceutical company focused on developing novel agents for central nervous system conditions. The Company's most advanced product candidate...

Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call

...lay number: 888-203-1112 (U.S. and Canada) / 719-457-0820 (international). Replay access code: 3898964. About Neurobiological Technologies, Inc. nti is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stag...

Neurobiological Technologies Sets Date for Second Quarter Financial Results

...lay number: 888-203-1112 (U.S. and Canada) / 719-457-0820 (international). Replay access code: 3898964. About Neurobiological Technologies, Inc. nti is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stag...

Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board

...n advisor to the company and we are pleased that he has agreed to continue to be available to advise us." About Neurobiological Technologies, Inc. nti is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stag...

Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering

... sale would be unlawful prior to registration or qualification under the securities laws of any such state. About Neurobiological Technologies, Inc. nti is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stag...

Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split

...ates and receive new post-split certificates. Conference Call Information nti will web cast its year end financial results conference call on September 1...l), replay access code: 9278405. About Neurobiological Technologies, Inc. nti is a specialty biopharmaceutical company with expertise in identifying and ...

Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq

...and which is expected to close after the above-referenced 30-day cure period expires on September 28, 2007. About Neurobiological Technologies, Inc. nti is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stag...

Quantitation of GAD67 Gene Expression in Prefrontal Cortex of Schizophrenia Patients Using the iCycler iQ Detection System and Molecular Beacons, Rev A

...e PCR primers and molecular beacons were synthesized commercially (IDT Corporation, Coralville, IA). PCR primers were designed using Vector nti software (InforMax, North Bethesda, MD). The melting temperatures (T m ) of the primer and probe sequences were determined by Ol...
Other Tags
(Date:3/26/2015)... TORONTO , March 26, 2015 ... premier family, social, recreation and athletic club, today announced ... designed to allow freedom of movement for members and ... "Following a comprehensive process, we selected FST,s IMID ... sophistication and convenience for our members and staff, in ...
(Date:3/24/2015)... 24, 2015   Crossmatch ™, a leading ... that its U.are.U ® 4500 Fingerprint Readers ... Bros . to achieve PCI compliance for Point-of-Sale ... to the POS terminal, protecting the retailer and ... breaches. With one-third of worldwide ...
(Date:3/23/2015)... Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... on CNBC television starting March 30 th . ... in New York markets. ... are excited about our new ad campaign following the recent ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
(Date:5/5/2015)... ProTexting, LLC – a premier ... Mobile Engagement Campaigns and other Mobile solutions, introduces e-mail ... now leverage the power of Mobile Marketing to expand ... e-mail addresses into the Constant Contact Platform. , ProTexting ... growing trend of multi-channel marketing would become more prominent ...
(Date:5/5/2015)... May 05, 2015 Okyanos, the leader ... Report today. The study was conducted to determine the ... osteoarthritis and sports-related injuries have had on ... was the most prevalent symptom reported at 73%, followed ... walking, standing and bending over. Over half of respondents, ...
(Date:5/5/2015)... On May, 5, 2015, My Positive Perspective host Jason Deierlein ... for youngsters to do this summer. As the episode began, ... starting a summer camp and how is it going to ... Upon a Party and I come to children’s birthday parties ... We play games, sing, and dance and have a great ...
(Date:5/5/2015)... 05, 2015 On April 8th, 2015, ... CA, Choices Recovery sponsored Durkin Entertainment’s “RockNRolla” EcoLuxe Lounge, ... producer of sustainable product placement in TV and film. ... top providers of ecologically sound and socially conscious products ... carpet event that makes appearances at various awards ceremonies ...
(Date:5/5/2015)... 2015 For the growing list of high ... data loggers. This data logger series is based ... for optimum performance throughout exposure to high temperatures and submersion ... are capable of storing up to 32,700 readings and feature ... one year or longer. All data loggers in the HiTemp140 ...
Breaking Medicine News(10 mins):Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 2Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 3Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 2Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 3Health News:My Positive Perspective Hosts Episode Informing People of a True Princess Summer Camp With Irene Rose 2Health News:Choices Recovery Mishawaka Talks About Overcoming Adversity with Actor Matthew Ziff at the “RockNRolla Movie Awards” EcoLuxe Lounge 2Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 2Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 3Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 4Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 5Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 6
Other Contents